PROCEPT BioRobotics Corporation specializes in advanced, image-guided surgical robotic systems designed for minimally invasive urologic surgery. Its core products, the AQUABEAM and HYDROS Robotic Systems, utilize real-time imaging, personalized treatment planning, and automated robotic execution to deliver heat-free waterjet ablation, known as Aquablation therapy. This technology is primarily used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). The company generates revenue through the sale of its capital equipment, single-use handpieces, consumables, and ongoing service contracts. While its primary market is the United States, PROCEPT BioRobotics also distributes its systems internationally through a direct sales organization and a network of distribution partners.
